The thoracic oncology community is discussing positive topline results from the Phase III OptiTROP-Lung06 trial, where the Trop-2 ADC sacituzumab tirumotecan (sac-TMT) plus pembrolizumab demonstrated superior PFS with a positive trend in OS versus chemo-IO in first-line PD-L1 negative non-squamous NSCLC. Also trending is the Phase III ELEVATE trial, which showed adjuvant ensartinib improved disease-free survival in resected ALK-positive NSCLC. A new meta-analysis found chemoimmunotherapy superior to PD-(L)1 monotherapy in advanced NSCLC with PD-L1 ≥50%.
“A meta-analysis of 24 phase III trials (5,546 patients) found superior outcomes with chemoimmunotherapy over PD-(L)1 monotherapy in advanced NSCLC with PD-L1 ≥50%: • OS: HR 0.85 • PFS: HR 0.61”
— @diegoadiazg · Chemoimmunotherapy in NSCLC · View post ↗📌 Amplified by @KolPulseAI
“Phase III OptiTROP-Lung06 meets primary endpoint. First-line sacituzumab tirumotecan (sac-TMT, Trop2 ADC) + pembro vs chemo + pembro in PD-L1 negative non-squamous NSCLC. Sac-TMT + pembro had superior PFS with OS trend. Will ADCs push out chemo?”
— @StephenVLiu · OptiTROP-Lung06 trial · View post ↗📌 Amplified by @KolPulseAI
“The phase III ELEVATE trial demonstrated that 2 years of adjuvant ensartinib after complete resection significantly improved disease-free survival in patients with ALK-positive NSCLC.”
— @ChandrakanthMv · ELEVATE trial · View post ↗
“Key point: We should NOT use of afatinib outside of EGFRm NSCLC”
— @TejasPatilMD · Afatinib use · View post ↗📌 Amplified by @KolPulseAI
The breast oncology community is discussing the FDA approval of the PI3K/mTOR inhibitor gedatolisib for PIK3CA wild-type, HR+/HER2- metastatic breast cancer after CDK4/6i therapy. Key clinical questions include the choice between doublet vs. triplet regimens and sequencing considerations for patients with ESR1 mutations. Separately, physicians are weighing the sequential use of tucatinib and trastuzumab deruxtecan (TDXd) for HER2+ brain metastases.
“Gedatolisib now approved for PIK3CAwt ER+ MBC. Very active regimen, many open questions: - triplet vs doublet. I’d favor doublet to optimize the benefit/risk ratio - IV infusions clearly add burden, shared decision making is key - if ESR1 mutant, SERD combos may be prioritized”
— @PTarantinoMD · Gedatolisib clinical considerations · View post ↗📌 Amplified by @KolPulseAI
“FDA approved gedatolisib ((RPI3K/AKT/mTOR-PAM inhibition) + fulvestrant ± palbociclib for PIK3CA-WT HR+/HER2- mBC post-CDK4/6i. First PAM inhibitor to land in the WT space.”
— @DrBarbiOnc · Gedatolisib approval context · View post ↗
“Tucatinib and TDXd are the two most effective drugs for patients facing HER2+ breast cancer brain metastases. Adding them together led to a PFS of 20 months for BM patients. For now best to use these agents sequentially and not together.”
— @drsarahsam · HER2+ brain metastases therapy · View post ↗📌 Amplified by @KolPulseAI
Quiet today — no notable KOL discussion in the last 48 hours.
In prostate cancer, the Phase 3 PROTEUS trial of perioperative apalutamide plus ADT met its dual primary endpoints in patients with high-risk localized/locally advanced disease. In kidney cancer, key topics include the updated NICE 2026 guideline and a new adjuvant treatment algorithm. One physician noted that '87% of stage 1a RCC in the UK is diagnosed incidentally,' highlighting challenges in early detection.
“87% of stage 1a RCC in the UK is diagnosed incidentally. A reminder of how challenging early detection remains in everyday clinical practice.”
— @drenriquegrande · Updated NICE RCC guideline · View post ↗
“Both dual primary endpoints were met”
— @urotoday · UroToday journal club — PROTEUS review · View post ↗
“Great to see this new algorithm that reflects the latest therapy for adjuvant RCC.”
— @scserendipity1 · Adjuvant RCC algorithm · View post ↗The myeloma/hematology community is discussing new prognostic markers, with a retrospective study suggesting high FCRL5 expression predicts poor survival in newly diagnosed patients. There is also a focus on the safety of advanced therapies, including real-world data on the risk of second primary malignancies with CAR T-cell therapy and the management of common toxicities. Ongoing debates center on the future of CAR-T and the development of fixed-duration therapeutic approaches.
“Retrospective study suggests high FCRL5 expression predicts poor treatment response & survival (median PFS 10.6 months vs. not reached, P = 0.002) and OS 13.2 months vs. not reached, P = 0.02)) in newly diagnosed myeloma:”
— @Myeloma_Doc · FCRL5 as a prognostic marker · View post ↗
“Now online: Second Primary Malignancy Risk in Patients with Multiple Myeloma Receiving CAR T-cell Therapy or Other Systemic Anticancer Treatments: A Real-World Comparative Study”
— @CCR_AACR · Second Primary Malignancy Risk · View post ↗
“A great opportunity to highlight trials that are ushering in the era of fixed-duration therapies for #myeloma”
— @Eddie_Cliff · Fixed-duration therapies · View post ↗📌 Amplified by @KolPulseAI
“3/⚠️ Safety remains the biggest challenge: 🔸 CRS: 67.5% 🔸 Infections: 60.3% (Grade ≥3: 38.3%) 🔸 Grade ≥3 neutropenia: 42.6%”
— @Abdallah81MD · Advanced therapy safety · View post ↗The hematology community is discussing a new meta-analysis of over 7,600 patients that quantifies non-relapse mortality (NRM) after CAR T-cell therapy, finding an overall rate of 6.8% with variations by product. Other discussions include a newly identified mechanism of resistance to tagraxofusp in BPDCN, linked to decreased TXNRD1, and monitoring strategies for patients on menin inhibitors.
“Non-relapse mortality post CAR-T = 6.8%”
— @Eddie_Cliff · CAR T-cell therapy NRM · View post ↗📌 Amplified by @KolPulseAI
“Decreased #TXNRD1 is associated with resistance to #tagraxofusp in blastic plasmacytoid dendritic cell neoplasms, as seen in phase II”
— @doctorpemm · Tagraxofusp resistance in BPDCN · View post ↗
“Our piece on monitoring patients on menin inhibitors.”
— @sanamloghavi · Menin inhibitor monitoring · View post ↗
“Chronic #GVHD is one of the most serious complications of allogenic #HSCT.”
— @IsbmtU · Chronic GVHD · View post ↗